<DOC>
	<DOC>NCT03081208</DOC>
	<brief_summary>The primary objective of this study is to confirm the efficacy of a single oral 900mg dose of nolasiban to increase the ongoing clinical pregnancy rate at 10 weeks post embryo transfer (ET) day.</brief_summary>
	<brief_title>Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI</brief_title>
	<detailed_description>The study is a prospective, randomized, parallel group, double-blind, placebo-controlled study to confirm the efficacy and the safety of the oxytocin receptor antagonist, nolasiban, in 760 women undergoing fresh embryo transfer following in vitro fertilisation (IVF) or intra-cytoplasmic sperm injection (ICSI).</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<criteria>Key Indicated for IVF/ICSI in the context of assisted reproductive technology (ART) Follow a gonadotropin releasing hormone (GnRH) antagonist protocol, single injection of human chorionic gonadotropin (hCG) for triggering final follicular maturation and luteal phase support with vaginal micronized progesterone. Single, fresh D3 or D5 embryo transfer Key Frozenthawed embryo transfer More than 20 oocytes in the current controlled ovarian hyperstimulation (COH) cycle Serum P4 greater than 1.5 ng/mL on the day of hCG administration</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>IVF</keyword>
	<keyword>ICSI</keyword>
</DOC>